Aclaris Therapeutics (ACRS) Q4 2025 earnings summary

Executive summary

• Achieved positive interim Phase 1a results for ATI-052, supporting rapid clinical advancement and extended dosing potential in immuno-inflammatory diseases.

• Initiated Phase 1b proof-of-concept trials for ATI-052 in atopic dermatitis and asthma, with top-line results expected in the second half of 2026.

• Lead ITK inhibitor ATI-9494 progressing toward IND application in the second half of 2026; ATI-2138 demonstrated strong hair regrowth in preclinical models.

Financial highlights

• Net loss for Q4 2025 was $19.8 million, a significant improvement from $96.6 million in Q4 2024; full-year net loss was $64.9 million, down from $132.1 million in 2024.

• Total revenue for Q4 2025 was $1.3 million, down from $9.2 million in Q4 2024; full-year revenue was $7.8 million, compared to $18.7 million in 2024, mainly due to a prior year milestone payment.

• R&D expenses increased to $16.6 million in Q4 2025 (from $9.0 million) and $52.6 million for the year (from $33.6 million), reflecting higher development costs for key pipeline assets.

• Cash, cash equivalents, and marketable securities totaled $151.4 million as of December 31, 2025, expected to fund operations into the second half of 2028.

Outlook and guidance

• Top-line results from ongoing Phase 1b trials of ATI-052 in AD and asthma anticipated in the second half of 2026.

• Phase 2 trial results for bosakitug in atopic dermatitis expected in the second half of 2026.

• IND application for ATI-9494 planned for the second half of 2026; Phase 2b program for ATI-052 targeted for initiation in the same period.

• Cash runway projected into the second half of 2028, excluding potential business development or additional trial costs.